Scientists test 'Click' to clear cancer imaging tracers
NCT ID NCT07009184
Summary
This early-phase study is testing a new imaging technique for cancers that have a protein called HER2, like some breast and stomach cancers. Researchers are using a special radioactive tracer attached to an antibody (trastuzumab) that targets HER2. After the tracer reaches the tumor, a second 'trigger' drug is given to quickly clear the leftover tracer from the bloodstream, aiming to get clearer pictures with less background noise and potentially fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud University Medical Center
RECRUITINGNijmegen, Gelderland, 6525 GS, Netherlands
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.